Long-term follow-up of stage 1-2 neuroblastoma
10.3969/j.issn.1000-3606.2014.05.003
- VernacularTitle:儿童1、2期神经母细胞瘤临床研究
- Author:
Ci PAN
;
Anan ZHANG
;
Qidong YE
;
Min ZHOU
;
Huiliang XUE
;
Jing CHEN
;
Changyin LUO
;
Shuhong SHEN
;
Jiangmin WANG
;
Yanjing TANG
;
Jingyan TANG
- Publication Type:Journal Article
- Keywords:
neuroblastoma;
therapy;
prognosis;
children
- From:
Journal of Clinical Pediatrics
2014;(5):410-412
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the clinical features, treatment scheme and long-term outcomes of stage 1、2 childhood neuroblastoma (NB). Methods The retrospective study included 49 newly diagnosed NB stage 1、2 patients from June 1998 to December 2010. Clinical data and long-term outcomes were analyzed. Results Twenty-four patients with stage 1 NB and twenty patients with stage 2 NB were found among all 237 patients with NB enrolled in this study. The median age at diagnosis was 25 months( 2 week to 9 year old),29 males and 20 females. Thirty-one patients (63.6%) without symptoms were discovered with tumor by physical or imaging examination. Thorax and abdomen were the most common sites of primary tumor (21 and 22 cases, accounting for 42.9% and 44.9% of all patients, respectively). Forty (81.6%) NB patients had favorable pathology classification. One patient was of MYCN amplification status. Urine vanilla mandelic acid was normal in 32 (91.4%) patients, and serum lactate dehydrogenase was less than five times of the normal value in all patients. Ten NB patients were treated ac-cording to the low-risk protocol who received surgery alone.Thirty-nine patients were treated according to intermediate-risk protocol who received both surgery and chemotherapy. All the patients achieved very good partial remission (100%).The medi-an follow-up period was 60 months(22 months to148months). Nine patients were lost after a follow up of 3 months in medi-an. The 2-、3-、5-year event free survival and overall survial of all 49 patients was 100%. Conclusions The prognosis for neu-roblastoma of stage 1、2 in this study was with 100%survival, which provides opportunity for further reduction of dosage and/or duration of episodes in chemotherapy.
